ABE treatment improves hyperlipidemia in rats with steroid-induced ONFH. Steroid hormone administration (the model group) induced marked hyperlipidemia, as indicated by significantly elevated TC (A), TG (B), LDL (C), ApoA1 (E), and ApoB (F) levels, but significantly decreased HDL levels (D). Doses of 10–22.5 g/kg ABE significantly reduced hyperlipidemia by decreasing TC (A), TG (B), LDL (C), ApoA1 (E), and ApoB (F) levels, and increasing HDL levels (D). Data are presented as the mean ± S.D. (n =20 for control, n =25 for model, n =20 for ABE 10 g/kg, ABE 15 g/kg, and 22.5 g/kg groups). # and ##: P <0.05 and P <0.01, respectively, in comparison with the control group. * and **: P <0.05 and P <0.01, respectively, in comparison with the model group.